title: First case of drug eruption due to ipragliflozin: Case report and review of the literature.
abstract: Ipragliflozin is a new drug for the treatment of diabetes mellitus. Its action of sodium-glucose cotransporter 2 (SGLT2) inhibition induces glucosuria and decreases blood glucose levels. We report the first case of ipragliflozin-related eczematous drug eruption and a review of the past literature on drug eruptions caused by SGLT2 inhibitors.
authors.affiliation: Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.
authors.forename: Natsuko
authors.initials: N
authors.lastname: Saito-Sasaki
authors.affiliation: Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.
authors.forename: Yu
authors.initials: Y
authors.lastname: Sawada
authors.affiliation: Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Nishio
authors.affiliation: Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.
authors.forename: Motonobu
authors.initials: M
authors.lastname: Nakamura
mesh_terms: D000368:Aged; D003920:Diabetes Mellitus / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D005960:Glucosides / Q000009:adverse effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male; D013876:Thiophenes / Q000009:adverse effects*
chemical_list: D005960:Glucosides; D007004:Hypoglycemic Agents; D013876:Thiophenes; C572941:ipragliflozin
keywords: SGLT2 inhibitor; case report; drug eruption; ipragliflozin; literature review